Abstract
Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead to broader kinase inhibition, which might be essential for the optimal suppression of tumor growth and induction of apoptosis. To reach these higher intratumoral concentrations, without encountering dose limiting toxicity, alternative TKI dosing strategies employing higher daily and high intermittent doses have been studied. In this systematic review, we evaluated the current clinical evidence to support (intermittent) high TKI dosing regimens. Methods: A systematic review was conducted in the following databases: PubMed®, EMBASE® and Cochrane Library
Original language | English (US) |
---|---|
Article number | 102171 |
Journal | Cancer Treatment Reviews |
Volume | 97 |
DOIs | |
State | Published - Jun 2021 |
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging